Price (delayed)
$27.32
Market cap
$326.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$349.71M
XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company's portfolio of partner-funded programs spans multiple stages
There are no recent dividends present for XOMA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.